Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $27.9300 (-2.44%) ($27.9300 - $27.9300) on Mon. Dec. 7, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.15% (three month average) | RSI | 41 | Latest Price | $27.9300(-2.44%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1% a day on average for past five trading days. | Weekly Trend | TGTX declines -3.2% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(60%) ARKK(56%) IBB(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.575% in a week (0% probabilities). VIXM(-37%) VXX(-34%) UUP(-19%) TBT(-2%) UNG(-0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.575% (StdDev 3.15%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $28.91 | 5 Day Moving Average | $27.94(-0.04%) | 10 Day Moving Average | $28.8(-3.02%) | 20 Day Moving Average | $28.91(-3.39%) | To recent high | -10.3% | To recent low | 17.7% | Market Cap | $3.537b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |